Crossmark

Age-associated differences in mucosal and systemic host responses to SARS-CoV-2 infection

Crossref DOI link: https://doi.org/10.1038/s41467-025-57655-3

Published Online: 2025-03-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hurst, Jillian H. https://orcid.org/0000-0001-5079-9920
Mohan, Aditya A.

Dalapati, Trisha https://orcid.org/0000-0001-6319-5253
George, Ian A.

Aquino, Jhoanna N.

Lugo, Debra J.

Pfeiffer, Trevor S.

Rodriguez, Javier

Rotta, Alexandre T. https://orcid.org/0000-0002-4406-2276
Turner, Nicholas A. https://orcid.org/0000-0003-0650-4894
Burke, Thomas W. https://orcid.org/0000-0003-0592-5822
McClain, Micah T. https://orcid.org/0000-0001-8034-1136
Henao, Ricardo https://orcid.org/0000-0003-4980-845X
DeMarco, C. Todd

Louzao, Raul

Denny, Thomas N.

Walsh, Kyle M. https://orcid.org/0000-0002-5879-9981
Xu, Zhaohui https://orcid.org/0000-0003-0645-1737
Mejias, Asuncion https://orcid.org/0000-0002-5983-8006
Ramilo, Octavio https://orcid.org/0000-0002-0565-5239
Woods, Christopher W. https://orcid.org/0000-0001-7240-2453
Kelly, Matthew S. https://orcid.org/0000-0001-8819-2315
Funding

Funding for this research was provided by:

U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01-AI161008, K23-AI135090, K23-AI135090)

This research was supported by a Merck Investigator Studies Program Grant (MISP #60495), and through funding provided by the Department of Pediatrics in the Duke University School of Medicine.
License Information

Text and Data Mining valid from 2025-03-10

Version of Record valid from 2025-03-10
More Information

Article History

Received: 19 October 2023

Accepted: 26 February 2025

First Online: 10 March 2025

Competing interests

: T.W.B. is a consultant for and owns equity in Biomeme, Inc. K.M.W. held a sponsored research project from Moderna Therapeutics, Inc. on immune correlates of congenital CMV infection. C.W.W. is a consultant for and owns equity in Biomeme, Inc. M.S.K. is a consultant for Merck & Co, Inc. and Invivyd. N.A.T. has received research contracts with PDI, Purio, and Basilea as well as consulting for Techspert. A.M. is a consultant for Merck, Pfizer, Moderna, Astra-Zeneca, Enanta, and Sanofi-Pasteur. O.R. has received research grants from the Bill & Melinda Gates Foundation, Merck, and Janssen; fees for participation in advisory boards from Merck, Sanofi-Pasteur, Pfizer, and Moderna; and fees for lectures from Pfizer, AstraZeneca, Merck, and Sanofi-Pasteur. All other authors declare that they have no competing interests.

Document is current

Any future updates will be listed below